Table 1.
Characteristics of 164 HCC patients before the surgery
| Variables | N | Mean ± SD |
|---|---|---|
| Gender (male/female) | 140/24 | – |
| Cirrhosis (+/−) | 154/9 | – |
| PVTT (+/−) | 44/117 | – |
| HBV (+/−) | 135/24 | – |
| BCLC (A/B/C) | 72/33/55 | – |
| Child–Pugh (A/B) | 145/18 | – |
| Age (≤60/>60, years) | 130/34 | 52.82±10.187 |
| Tumor size (≤5/>5, cm) | 48/116 | 9.26±4.76 |
| AFP (≤400/>400, ng/μL) | 79/82 | 588.50±549.47 |
| GGT (<7/7–50/>50, U/L) | 0/39/125 | 161.06±159.56 |
| ALT (<5/5–40/>40, U/L) | 0/72/92 | 59.71±64.19 |
| AST (<8/8–40/>40, U/L) | 0/45/119 | 76.99±63.73 |
| ALP (<40/40–150/>150, U/L) | 0/122/42 | 130±82.55 |
| Alb (<34/34–48/>48, g/L) | 24/137/3 | 39.35±5.95 |
| PA (<200/200–400/>400, mg/L) | 128/24/0 | 142.47±55.51 |
| PT (<11/11–14.3/>14.3, s) | 6/111/47 | 13.53±1.66 |
| ApoA1 (<1.2/1.2–1.6/>1.6, g/L) | 119/41/4 | 0.98±0.32 |
| ApoB (<0.8/0.8–1.05/>1.05, g/L) | 89/48/27 | 0.81±0.32 |
| LDL-C (<2.07/2.07–3.12/>3.12, mmol/L) | 37/82/45 | 2.81±1.07 |
| HDL-C (≤1.02/>1.02, mmol/L) | 57/107 | 1.20±0.45 |
| Cholesterol (≤5.17/>5.17, mmol/L) | 134/30 | 4.35±1.11 |
| TBA (≤9.67/>9.67, μmol/L) | 55/95 | 19.78±23.96 |
Abbreviations: AFP, α-fetoprotein; ALP, alkaline phosphatase; ALT, alanine amino transferase; AST, aspartate transaminase; Alb, albumin; ApoA1, apolipoprotein A1; ApoB, apolipoprotein B; BCLC, Barcelona Clinic Liver Cancer; GGT, g-glutamyl transpeptidase; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; PA, prealbumin; PT, prothrombin time; PVTT, portal vein tumor thrombus; TBA, total bile acid.